Vaxart, Inc. (OTCQX: VXRT), a South San Francisco-based clinical-stage biotechnology company, will present its proprietary oral recombinant vaccine platform at two high-profile industry events anchored around the BIO International Convention, scheduled for June 22–25, 2026, at the San Diego Convention Center. Members of the company's management team will also appear at the Taiwan Biotech Forum running concurrently with BIO 2026.
Vaxart's platform centers on orally administered tablet-based vaccines designed to stimulate mucosal immunity — a mechanism of growing interest not only in vaccine science but also in the broader functional-ingredients sector, where gut-associated lymphoid tissue (GALT) activation is an emerging clinical endpoint in probiotic and postbiotic research. The company's delivery technology is engineered to survive gastric transit, a bioavailability challenge that functional food and dietary supplement formulators know well from encapsulated probiotic and enzyme applications.
While Vaxart's pipeline is squarely pharmaceutical, its oral-delivery science is directionally relevant to the nutraceutical and functional food categories. Innovators in the finished formulation space — particularly those working with heat-sensitive actives, live cultures measured in CFU, or acid-labile botanicals — are tracking advances in enteric and tablet-matrix delivery that parallel Vaxart's core engineering work. The global oral drug delivery market, which encompasses both pharmaceutical and nutraceutical applications, has drawn substantial investment as operators seek alternatives to injectable or refrigerated formats. For more on delivery innovation intersecting the supplement space, see our coverage of encapsulation technologies in functional ingredients and probiotic stability and CFU viability standards.
Vaxart's BIO 2026 appearances position the company for potential partnership discussions at a convention that routinely draws licensing, co-manufacturing, and white-label deal flow across the life sciences spectrum. Taiwan's parallel forum signals the company's intent to engage Asia-Pacific stakeholders — a region where functional food and nutraceutical consumption is accelerating, and where regulatory pathways for novel delivery systems are evolving rapidly.
For functional food and supplement industry operators monitoring the convergence of pharmaceutical-grade delivery science with nutraceutical applications, Vaxart's platform presentations offer a window into next-generation bioavailability engineering. Whether that translates into licensing opportunities, co-development interest, or simply a benchmark for oral-delivery standards, BIO 2026 will be a data point worth tracking. Coverage is produced in partnership with Food & Beverage Magazine.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.